Zydus Cadila gets USFDA nod to market generic tension headache tablets
- IBEF
- July 20, 2020
Zydus Cadila, an Indian drug firm, received final approval from the United States Food and Drug Administration (USFDA) to market generic Butalbital, Acetaminophen and Caffeine combination tablets to treat symptoms of tension headaches.
It received final approval from USFDA to market Butalbital, Acetaminophen and Caffeine tablets in strengths of 50mg/325mg/40 mg, as per the Zydus Cadila statement.
The company will manufacture the drug at Nesher Pharma's manufacturing facility at St. Louis in the US, it added.
This combination medication is used to treat symptom complex of tension (or muscle contraction) headaches, Zydus Cadila said.
So far, the group has received 294 approvals and has filed over 390 abbreviated new drug applications (ANDAs) since the commencement of the filing process, it added.
Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.
Partners
